# Assess the Absorption, Distribution, Metabolism and Excretion of AZD7325 After Intravenous and Oral Administration

> **NCT00940641** · PHASE1 · SUSPENDED · sponsor: **AstraZeneca** · enrollment: 8 (estimated)

## Conditions studied

- Absorption
- Distribution
- Metabolism
- Excretion

## Interventions

- **DRUG:** AZD7325
- **DRUG:** AZD7325

## Key facts

- **NCT ID:** NCT00940641
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2009-08
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 8 (ESTIMATED)
- **Why stopped:** Study withdrawn prior to enrollment due to AZ business decision unrelated to safety.
- **Last updated:** 2011-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00940641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00940641, "Assess the Absorption, Distribution, Metabolism and Excretion of AZD7325 After Intravenous and Oral Administration". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00940641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*